These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28193167)

  • 1. Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease.
    Lahat A; Kopylov U; Neuman S; Levhar N; Yablecovitch D; Avidan B; Weiss B; Ben-Horin S; Eliakim R;
    BMC Gastroenterol; 2017 Feb; 17(1):27. PubMed ID: 28193167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy.
    Klang E; Kopylov U; Eliakim R; Rozendorn N; Yablecovitch D; Lahat A; Ben-Horin S; Amitai MM
    Clin Radiol; 2017 Sep; 72(9):798.e7-798.e13. PubMed ID: 28506799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography.
    Quaia E; Cabibbo B; Sozzi M; Gennari AG; Pontello M; Degrassi F; Cova MA
    Acad Radiol; 2014 Oct; 21(10):1225-32. PubMed ID: 24998692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease?
    Murad HA
    Acta Gastroenterol Belg; 2016; 79(3):349-354. PubMed ID: 27821031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study.
    Melmed GY; Dubinsky MC; Rubin DT; Fleisher M; Pasha SF; Sakuraba A; Tiongco F; Shafran I; Fernandez-Urien I; Rosa B; Papageorgiou NP; Leighton JA
    Gastrointest Endosc; 2018 Dec; 88(6):947-955.e2. PubMed ID: 30086261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease.
    Somwaru AS; Khanijow V; Katabathina VS
    BMC Gastroenterol; 2019 Dec; 19(1):210. PubMed ID: 31805875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
    Höög CM; Bark LÅ; Broström O; Sjöqvist U
    Scand J Gastroenterol; 2014 Sep; 49(9):1084-90. PubMed ID: 24853318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching.
    Parente F; Molteni P; Bollani S; Maconi G; Vago L; Duca PG; Rembacken B; Axon AT; Bianchi Porro G
    Scand J Gastroenterol; 1997 Nov; 32(11):1140-6. PubMed ID: 9399396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
    Bojarski C; Epple HJ; Kirstein FW; Fromm M; Bisson S; Riecken EO; Schulzke JD
    Z Gastroenterol; 2000 Mar; 38(3):211-9. PubMed ID: 10768243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
    Tan WC; Hogan J; Purkayastha SK; Lombard M; Krasner N
    Int J Clin Pract; 1997 Jun; 51(4):214-6. PubMed ID: 9287260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease.
    Egea Valenzuela J; Pereñíguez López A; Pérez Fernández V; Alberca de Las Parras F; Carballo Álvarez F
    Rev Esp Enferm Dig; 2016 Jul; 108(7):394-400. PubMed ID: 27312194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein microarray analysis for detection of serum anti-Helicobacter pylori antibodies after eradication therapy: a clinical follow-up.
    Cui M; Wei H; Mu F; Yi G; Fu Y; Yue L
    Hepatogastroenterology; 2015; 62(138):503-6. PubMed ID: 25916090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Enteric Crohn's Capsule [Eliakim] Score Reliability and Responsiveness to Change in Active Crohn's Disease.
    Ukashi O; Lahat A; Ungar B; Levy H; Finkel O; Eidler P; Ben-Horin S; Eliakim R; Kopylov U
    J Crohns Colitis; 2024 Oct; 18(10):1622-1630. PubMed ID: 38721918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn's disease.
    D'Incà R; Sturniolo G; Cassaro M; di Pace C; Longo G; Callegari I; Rugge M
    Dig Dis Sci; 1998 May; 43(5):988-92. PubMed ID: 9590412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.
    Domachevsky L; Leibovitzh H; Avni-Biron I; Lichtenstein L; Goldberg N; Nidam M; Groshar D; Bernstine H; Ben-Bassat O
    Contrast Media Mol Imaging; 2017; 2017():7167292. PubMed ID: 29097934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.
    Bickelhaupt S; Pazahr S; Chuck N; Blume I; Froehlich JM; Cattin R; Raible S; Bouquet H; Bill U; Rogler G; Frei P; Boss A; Patak MA
    Neurogastroenterol Motil; 2013 Jun; 25(6):467-73. PubMed ID: 23495824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.